PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION

Mount Sinai launches clinical trial to treat chronic pulmonary sarcoidosis

2013-01-31
(Press-News.org) Patients are currently being enrolled in the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis. The trial is being conducted by researchers at the Icahn School of Medicine at Mount Sinai.

Mount Sinai has the largest Sarcoidosis Service in the world and is one of only two institutions in the country participating in the trial; the other is the University of Cincinnati. Mount Sinai is a National Institutes of Health Center of Excellence for research in sarcoidosis.

"The current standard treatment for chronic pulmonary sarcoidosis is corticosteroids," said Adam Morgenthau, MD, principal investigator of the study and Director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at Mount Sinai. "Many patients don't respond to these drugs and those who do often develop long-term complications. We are hopeful this study will lead to new treatments to improve lung function and quality of life."

Sarcoidosis is a rare inflammatory disease that can affect any organ but most commonly involves the lungs. Patients with pulmonary sarcoidosis typically exhibit symptoms of shortness of breath, cough and/or wheeze. It affects men and women of all ages and races worldwide. However, it occurs mostly in people ages 20 to 40, African Americans, especially women, and people of Asian, German, Irish, Puerto Rican and Scandinavian origin, according to the National Institutes of Health. The randomized placebo Phase II clinical trial at Mount Sinai for patients with sarcoidosis is designed to assess the safety, tolerability and efficacy of an antibody directed against macrophage colony-stimulating factor (m-CSF), a protein associated with the development of sarcoidosis. During a Phase I clinical trial for patients with rheumatoid arthritis (RA), the antibody was well tolerated in healthy people as well as patients with RA.

"This study has both clinical and basic science applications," said Dr. Morgenthau. "In addition to determining whether patients' symptoms improve with this treatment, we will examine cell signaling pathways and immune responses in the trial participants which will help us better understand the biology of sarcoidosis and ultimately lead to the development of therapies that target the immune response."

### To be eligible for the study, patients must be taking corticosteroids daily for chronic pulmonary sarcoidosis and lung impairment. As many as 90 accepted patients will receive infusion therapy every two weeks for 12 weeks, take CT and PET scans and submit questionnaires. Patients interested in participating in the trial should contact the Clinical Trials Office at 212-241-9538 or visit http://www.mssm.edu/research/resources/office-of-clinical-research.

The Phase I and II clinical trials have been funded by Pfizer.


ELSE PRESS RELEASES FROM THIS DATE:

New semiconductor research may extend integrated circuit battery life tenfold

2013-01-31
Researchers at Rochester Institute of Technology, international semiconductor consortium SEMATECH and Texas State University have demonstrated that use of new methods and materials for building integrated circuits can reduce power—extending battery life to 10 times longer for mobile applications compared to conventional transistors. The key to the breakthrough is a tunneling field effect transistor. Transistors are switches that control the movement of electrons through material to conduct the electrical currents needed to run circuits. Unlike standard transistors, which ...

Satellite image shows eastern US severe weather system

Satellite image shows eastern US severe weather system
2013-01-31
A powerful cold front moving from the central United States to the East Coast is wiping out spring-like temperatures and replacing them with winter-time temperatures with powerful storms in between. An image released from NASA using data from NOAA's GOES-13 satellite provides a stunning look at the powerful system that brings a return to winter weather in its wake. On Jan. 30 at 1825 UTC (1:25 p.m. EST), NOAA's GOES-13 satellite captured an image of clouds associated with the strong cold front. The visible GOES-13 image shows a line of clouds that stretch from Canada ...

NASA-NOAA's Suomi NPP satellite sees powerful Cyclone Felleng

NASA-NOAAs Suomi NPP satellite sees powerful Cyclone Felleng
2013-01-31
False-colored night-time satellite imagery from NASA-NOAA's Suomi NPP satellite clearly shows bands of thunderstorms wrapping into the eye of Cyclone Felleng as it parallels the coast of eastern Madagascar. The Visible Infrared Imager Radiometer Suite (VIIRS) aboard NASA-NOAA's Suomi NPP satellite captured a night-time image of Cyclone Felleng when it was located east of Madagascar (4:09 p.m. EST/Jan. 30 at 12:09 a.m. local time, Madagascar). The image was created at the University of Wisconsin-Madison and was false colored to reveal temperatures. The image shows powerful ...

Rutgers physics professors find new order in quantum electronic material

2013-01-31
Two Rutgers physics professors have proposed an explanation for a new type of order, or symmetry, in an exotic material made with uranium – a theory that may one day lead to enhanced computer displays and data storage systems and more powerful superconducting magnets for medical imaging and levitating high-speed trains. Their discovery, published in this week's issue of the journal Nature, has piqued the interest of scientists worldwide. It is one of the rare theory-only papers that this selective publication accepts. Typically the journal's papers describe results of ...

Archaic Native Americans built massive Louisiana mound in less than 90 days

Archaic Native Americans built massive Louisiana mound in less than 90 days
2013-01-31
Nominated early this year for recognition on the UNESCO World Heritage List, which includes such famous cultural sites as the Taj Mahal, Machu Picchu and Stonehenge, the earthen works at Poverty Point, La., have been described as one of the world's greatest feats of construction by an archaic civilization of hunters and gatherers. Now, new research in the current issue of the journal Geoarchaeology, offers compelling evidence that one of the massive earthen mounds at Poverty Point was constructed in less than 90 days, and perhaps as quickly as 30 days — an incredible ...

REACH news: European ombudsman takes up PETA complaint

2013-01-31
London – In response to a complaint by People for the Ethical Treatment of Animals (PETA), the European Ombudsman has launched an inquiry into the actions of the European Union (EU) agency responsible for the administration of the REACH chemical-testing program, which is expected to consume millions of animals in toxicity tests. PETA's complaint, submitted in July 2012, alleges that the European Chemicals Agency (ECHA) is not properly investigating cases in which animal testing could be avoided under the rules of REACH. PETA maintains that evidence derived from public documents ...

Researchers harness nature to produce the fuel of the future

2013-01-31
Hydrogen has tremendous potential as an eco-friendly fuel, but it is expensive to produce. Now researchers at Princeton University and Rutgers University have moved a step closer to harnessing nature to produce hydrogen for us. The team, led by Princeton chemistry professor Annabella Selloni, takes inspiration from bacteria that make hydrogen from water using enzymes called di-iron hydrogenases. Selloni's team uses computer models to figure out how to incorporate the magic of these enzymes into the design of practical synthetic catalysts that humans can use to produce ...

Patients can emit small, influenza-containing particles into the air during routine care

2013-01-31
[EMBARGOED FOR JAN. 31, 2013] A new study suggests that patients with influenza can emit small virus-containing particles into the surrounding air during routine patient care, potentially exposing health care providers to influenza. Published in The Journal of Infectious Diseases, the findings raise the possibility that current influenza infection control recommendations may not always be adequate to protect providers from influenza during routine patient care in hospitals. Werner E. Bischoff, MD, PhD, and colleagues from the Wake Forest School of Medicine in North Carolina ...

Social networking: Gen Xers connect online as often as they socialize in person

2013-01-31
ANN ARBOR--- Young adults in Generation X are as likely to connect with friends, family and co-workers online as they are in person, according to a University of Michigan study. In a typical month, adults in their late 30s report that they engaged in about 75 face-to-face contacts or conversations, compared to about 74 electronic contracts through personal emails or social media. "Given the speed of emerging technologies, it is likely that electronic contacts will continue to grow in the years ahead, eventually exceeding face-to-face interactions," says Jon D. Miller, ...

Debts That Remain after a Bankruptcy

2013-01-31
Debts that remain after a bankruptcy If you have had to file bankruptcy recently due to the sluggish economy, you're not alone. Bankruptcy has many benefits, but the main reason to file is to receive a discharge of your debts. Normally, once you receive a discharge, you are under no further legal obligation to pay the debt. Although the bankruptcy discharge is a powerful tool against many types of debt, such a medical bills and credit card debt, there are certain types of debt that cannot be discharged in a bankruptcy. Nondischargeable debts To a certain extent, ...

LAST 30 PRESS RELEASES:

Scientists model 'true prevalence' of COVID-19 throughout pandemic

New breakthrough to help immune systems in the fight against cancer

Through the thin-film glass, researchers spot a new liquid phase

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Brain's 'memory center' needed to recognize image sequences but not single sights

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

Changes in disparities in access to care, health after Medicare eligibility

Use of high-risk medications among lonely older adults

65+ and lonely? Don't talk to your doctor about another prescription

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

Plant root-associated bacteria preferentially colonize their native host-plant roots

Rare inherited variants in previously unsuspected genes may confer significant risk for autism

International experts call for a unified public health response to NAFLD and NASH epidemic

International collaboration of scientists rewrite the rulebook of flowering plant genetics

Improving air quality reduces dementia risk, multiple studies suggest

Misplaced trust: When trust in science fosters pseudoscience

Two types of blood pressure meds prevent heart events equally, but side effects differ

New statement provides path to include ethnicity, ancestry, race in genomic research

Among effective antihypertensive drugs, less popular choice is slightly safer

Juicy past of favorite Okinawan fruit revealed

Anticipate a resurgence of respiratory viruses in young children

Anxiety, depression, burnout rising as college students prepare to return to campus

Goal-setting and positive parent-child relationships reduce risk of youth vaping

New research identifies cancer types with little survival improvements in adolescents and young adul

Oncotarget: Replication-stress sensitivity in breast cancer cells

Oncotarget: TERT and its binding protein: overexpression of GABPA/B in gliomas

Development of a novel technology to check body temperature with smartphone camera

The mechanics of puncture finally explained

Extreme heat, dry summers main cause of tree death in Colorado's subalpine forests

[Press-News.org] Mount Sinai launches clinical trial to treat chronic pulmonary sarcoidosis